Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action

Type 2 diabetes is a syndrome characterized by relative insulin deficiency, insulin resistance and increased hepatic glucose output. Medications used to treat the disease are designed to correct one or more of these metabolic abnormalities. Current recommendations of the American Diabetes Associatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenzati, Bartolomeo, Zucco, Chiara, Miglietta, Sara, Lamberti, Federico, Bruno, Graziella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034109/
https://www.ncbi.nlm.nih.gov/pubmed/27713388
http://dx.doi.org/10.3390/ph3093005
_version_ 1782317933126483968
author Lorenzati, Bartolomeo
Zucco, Chiara
Miglietta, Sara
Lamberti, Federico
Bruno, Graziella
author_facet Lorenzati, Bartolomeo
Zucco, Chiara
Miglietta, Sara
Lamberti, Federico
Bruno, Graziella
author_sort Lorenzati, Bartolomeo
collection PubMed
description Type 2 diabetes is a syndrome characterized by relative insulin deficiency, insulin resistance and increased hepatic glucose output. Medications used to treat the disease are designed to correct one or more of these metabolic abnormalities. Current recommendations of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) include diet and exercise as first-line therapy plus hypoglycemic drugs. Actually there are seven distinct classes of anti-hyperglicemic agents, each of them displaying unique pharmacologic properties. The aim of this review is to describe the pathophysiological basis of their mechanism of action, a necessary step to individualize treatment of diabetic people, taking into proper consideration potential benefits and secondary effects of drugs.
format Online
Article
Text
id pubmed-4034109
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-40341092014-05-27 Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action Lorenzati, Bartolomeo Zucco, Chiara Miglietta, Sara Lamberti, Federico Bruno, Graziella Pharmaceuticals (Basel) Review Type 2 diabetes is a syndrome characterized by relative insulin deficiency, insulin resistance and increased hepatic glucose output. Medications used to treat the disease are designed to correct one or more of these metabolic abnormalities. Current recommendations of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) include diet and exercise as first-line therapy plus hypoglycemic drugs. Actually there are seven distinct classes of anti-hyperglicemic agents, each of them displaying unique pharmacologic properties. The aim of this review is to describe the pathophysiological basis of their mechanism of action, a necessary step to individualize treatment of diabetic people, taking into proper consideration potential benefits and secondary effects of drugs. MDPI 2010-09-15 /pmc/articles/PMC4034109/ /pubmed/27713388 http://dx.doi.org/10.3390/ph3093005 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Lorenzati, Bartolomeo
Zucco, Chiara
Miglietta, Sara
Lamberti, Federico
Bruno, Graziella
Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action
title Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action
title_full Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action
title_fullStr Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action
title_full_unstemmed Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action
title_short Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action
title_sort oral hypoglycemic drugs: pathophysiological basis of their mechanism of action
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034109/
https://www.ncbi.nlm.nih.gov/pubmed/27713388
http://dx.doi.org/10.3390/ph3093005
work_keys_str_mv AT lorenzatibartolomeo oralhypoglycemicdrugspathophysiologicalbasisoftheirmechanismofaction
AT zuccochiara oralhypoglycemicdrugspathophysiologicalbasisoftheirmechanismofaction
AT migliettasara oralhypoglycemicdrugspathophysiologicalbasisoftheirmechanismofaction
AT lambertifederico oralhypoglycemicdrugspathophysiologicalbasisoftheirmechanismofaction
AT brunograziella oralhypoglycemicdrugspathophysiologicalbasisoftheirmechanismofaction

Ejemplares similares